Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-171P is a pseudogene derived from the U6 small nuclear RNA (snRNA) gene, one of many non-functional copies scattered throughout the vertebrate genome as a result of retrotransposon-mediated duplication events[5][3][4]. U6 snRNA itself is a crucial component of the spliceosome in eukaryotic cells, essential for the removal of introns from pre-mRNA during RNA splicing[1][3]. However, pseudogenes like RNU6-171P do not produce active RNA molecules or proteins, and generally have no biological activity or disease relevance except potentially in genome structure or regulation of parental gene expression. The occurrence of numerous U6 snRNA pseudogenes in the genome is an indicator of the gene's evolutionary significance, but they are not studied as therapeutic targets[3][5].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 171, pseudogene (RNU6-171P).